Globus Medical, Inc. $GMED Holdings Raised by Terril Brothers Inc.

Terril Brothers Inc. grew its stake in Globus Medical, Inc. (NYSE:GMED) by 7,653.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 253,910 shares of the medical device company’s stock after buying an additional 250,635 shares during the quarter. Globus Medical accounts for approximately 5.6% of Terril Brothers Inc.’s portfolio, making the stock its 7th biggest position. Terril Brothers Inc. owned approximately 0.19% of Globus Medical worth $14,986,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GMED. HB Wealth Management LLC lifted its stake in Globus Medical by 4.7% in the first quarter. HB Wealth Management LLC now owns 3,804 shares of the medical device company’s stock worth $278,000 after acquiring an additional 170 shares during the last quarter. Whittier Trust Co. lifted its position in shares of Globus Medical by 46.5% during the 1st quarter. Whittier Trust Co. now owns 580 shares of the medical device company’s stock worth $42,000 after purchasing an additional 184 shares during the last quarter. Capital Investment Counsel Inc grew its stake in shares of Globus Medical by 0.9% during the first quarter. Capital Investment Counsel Inc now owns 22,490 shares of the medical device company’s stock worth $1,646,000 after purchasing an additional 200 shares in the last quarter. First Horizon Advisors Inc. increased its holdings in Globus Medical by 30.9% in the first quarter. First Horizon Advisors Inc. now owns 872 shares of the medical device company’s stock valued at $64,000 after buying an additional 206 shares during the last quarter. Finally, GAMMA Investing LLC raised its stake in Globus Medical by 20.3% in the first quarter. GAMMA Investing LLC now owns 1,514 shares of the medical device company’s stock valued at $111,000 after buying an additional 256 shares in the last quarter. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Globus Medical Price Performance

Globus Medical stock opened at $60.73 on Friday. The business has a 50 day simple moving average of $59.41 and a 200-day simple moving average of $60.27. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $94.93. The stock has a market capitalization of $8.20 billion, a PE ratio of 23.36, a price-to-earnings-growth ratio of 1.68 and a beta of 1.12.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, August 7th. The medical device company reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.10. The company had revenue of $745.34 million during the quarter, compared to the consensus estimate of $738.91 million. Globus Medical had a net margin of 13.58% and a return on equity of 10.65%. Globus Medical’s quarterly revenue was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.75 EPS. As a group, equities research analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on GMED shares. Morgan Stanley lowered their price objective on Globus Medical from $75.00 to $68.00 and set an “overweight” rating for the company in a research report on Tuesday, July 15th. Wells Fargo & Company lowered their price target on Globus Medical from $76.00 to $66.00 and set an “overweight” rating for the company in a report on Friday, August 8th. Canaccord Genuity Group dropped their price target on shares of Globus Medical from $97.00 to $90.00 and set a “buy” rating on the stock in a research note on Tuesday, July 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Globus Medical in a research report on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Globus Medical from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Seven equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $84.55.

Insider Buying and Selling

In other Globus Medical news, Director Ann D. Rhoads sold 10,000 shares of Globus Medical stock in a transaction that occurred on Monday, September 15th. The stock was sold at an average price of $58.46, for a total value of $584,600.00. Following the sale, the director owned 25,384 shares of the company’s stock, valued at approximately $1,483,948.64. The trade was a 28.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.51% of the stock is currently owned by insiders.

Globus Medical Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.